2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapy
2010
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMalignant T cellsTreatment strategiesT cellsManagement of CTCLPredictable adverse effectsRapid disease controlConservative treatment strategyFront-line therapyEarly-stage diseaseIndolent clinical courseMature T-cell lymphomasStem cell transplantInterleukin-2 receptorHistone deacetylase inhibitorsSystemic chemotherapyExtracorporeal photopheresisInitial managementSézary syndromeClinical courseCurative therapyBiological therapyCell transplantMycosis fungoides
2007
Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma
Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews 2007, 33: 146-160. PMID: 17275192, DOI: 10.1016/j.ctrv.2006.08.006.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMycosis fungoidesTherapeutic optionsPrimary cutaneous T-cell lymphomaSkin-directed therapiesAggressive clinical courseCurrent therapeutic optionsNon-Hodgkin lymphomaNovel therapeutic targetCritical unmet needWorld Health OrganizationCharacteristic clinicopathologicImmunologic changesCutaneous lymphomasDurable responsesSystemic therapyClinical courseDefinitive treatmentSezary syndromeImmunophenotypic featuresTreatment of cancerAvailable therapiesCell transplantationDisease progression
2005
Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma
Huang Z, Higgins B, Foss F. Activity of Gallium Nitrate in Refractory Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2005, 6: 43-45. PMID: 15989706, DOI: 10.3816/clm.2005.n.026.Peer-Reviewed Original Research